Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 1, Issue 4
December 16 2024
In Progress
Issue Cover

Lymphoid Neoplasia

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
Paola Ghione,Kurt S. Bantilan,Erel Joffe,M. Lia Palomba,Ariela Noy,Philip Caron,Paul Hamlin,Anita Kumar,Matthew Matasar,Colette Owens,Alison Moskowitz,Lorenzo Falchi,David Straus,Steven Horwitz,Gilles Salles,Ahmet Dogan,Andrew D. Zelenetz
View Articletitled, CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
COVID-19 vaccination in patients with classic and variant hairy cell leukemia
Robert J. Kreitman,Lacey James,Julie Feurtado,Holly Eager,Olena Sierra Ortiz,Mory Gould,Isaac Shpilman,Hong Zhou,Peter D. Burbelo,Jeffrey I. Cohen,Hao-Wei Wang,Constance M. Yuan,Evgeny Arons
View Articletitled, COVID-19 vaccination in patients with classic and variant hairy cell leukemia
BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis
Wangisa Dunuwille,William C. Wilson,Hassan Bjeije,Nancy Issa,Wentao Han,Tyler M. Parsons,Andrew L. Young,Infencia Xavier Raj,Aishwarya Krishnan,Tarang Gaur,Eunice S. Wang,Andrew P. Weng,Matthew C. Stubbs,Hamza Celik,Amanda F. Cashen,John R. Edwards,Grant A. Challen
View Articletitled, BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis
Supplemental data
Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma
Eunice Lai,Yu Yang Soon,Ainsley Ryan Yan Bin Lee,Shi Yin Wong,Cinnie Yentia Soekojo,Melissa Ooi,Wee Joo Chng,Sanjay de Mel
View Articletitled, Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma
Supplemental data
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy
Joshua W. D. Tobin,Venkata A. Chikatamarla,Marko Matic,Alison Griffin,Rakin Chowdhury,Ross Salvaris,Amanda Goh,Harrison Black,Tsz Hung Tong,Callum Birks,Sanjiv Jain,Elizabeth Goodall,Shreerang Sirdesai,Thomas Trevis,Elizabeth Steinepreis,Yiyang Chen,Li Li,Glenn Broadby,Naadir Gutta,Kirk Morris,Tara Cochrane,Judith Trotman,Dipti Talaulikar,Jake Shortt,Georgina Hodges,Eliza A. Hawkes,Chan Y. Cheah,Allison Barraclough,Kate Manos,Anna Johnston,Jane Royle,Patrizia Mondello,Stephen M. Ansell,Greg Hapgood
View Articletitled, Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy
Supplemental data

TRANSLATIONAL RESEARCH

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies
Ella Troy,Joseph Caporale,Yasemin Sezgin,Marcelo S. F. Pereira,Gregory Behbehani,Justin Lyberger,Dean A. Lee,Meisam Naeimi Kararoudi
View Articletitled, CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies
Supplemental data
Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML
Sara H. Small,Ricardo E. Perez,Elspeth M. Beauchamp,Aneta H. Baran,Stephen D. Willis,Mariafausta Fischietti,Michael Schieber,Masha Kocherginsky,Diana Saleiro,Leonidas C. Platanias
View Articletitled, Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML
Supplemental data

RESEARCH LETTER

A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy
Clinical Trials & Observations
Elizabeth A. Brem,Kevin Shieh,Dennis Juarez,Roberta Buono,Deepa Jeyakumar,Susan O’Brien,Thomas H. Taylor,David A. Fruman
View Articletitled, A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy
Supplemental data
Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation
Jinjun Cheng,Rachel Mariani,Jyotinder Nain Punia,Marimar de la Cruz Bonilla,Pichayut Nithagon,Metin Ozdemirli,Wen Shuai,Larry Wang,Oussama Abla,Shunyou Gong
View Articletitled, Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation
Supplemental data

MYELOID NEOPLASIA

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia
Kuo-Kai Chin,Yannis Valtis,Andriy Derkach,Meira Yisraeli Salman,Leora Boussi,Jenna Ciervo,Mark B. Geyer,Jae H. Park,Martin S. Tallman,Jacob L. Glass,Aaron D. Goldberg,Eytan M. Stein
View Articletitled, Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma
Clinical Trials & Observations
Amrita Y. Krishnan,Krina K. Patel,Meera Mohan,Sundar Jagannath,Ruben Niesvizky,Rebecca W. Silbermann,Ziji Yu,Tao Long,Scott R. P. McDonnell,Deborah Berg,Keith E. Stockerl-Goldstein
View Articletitled, Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma
Supplemental data
All Issues

Advertisement intended for health care professionals

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 

Advertisement intended for health care professionals

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals